Skip to main content

Table 3 Univariate and multivariate analyses for prediction of LVZ in the whole cohort

From: Left atrial remodeling and voltage-guided ablation outcome in persistent atrial fibrillation patients according to CHA2DS2-VASc score

VARIABLE

Univariate Analysis

Multivariate Analysis

OR

95% CI

P Value

OR

95% CI

P Value

Female with CHA2DS2-VASc score ≥ 3

6.550

2.676–16.032

< 0.001

9.112

1.219–68.131

0.031

Male with CHA2DS2-VASc score ≥ 3

1.684

0.629–4.512

0.300

…

…

…

Dyslipidemia

0.924

0.424–2.016

0.843

…

…

…

OSA

1.867

0.770–4.526

0.167

…

…

…

BMI

0.886

0.814–0.965

0.006

0.856

0.700-1.048

0.133

eGFR

0.964

0.942–0.986

0.002

0.988

0.950–1.029

0.567

Coronary artery disease

0.527

0.174–1.599

0.258

…

…

…

LAIVI

1.089

1.044–1.135

< 0.001

1.071

1.018–1.128

0.009

Time to treatment

1.000

1.000-1.001

0.059

1.000

1.000-1.001

0.213

AF duration > 6 months

0.337

0.110–1.037

0.058

1.463

0.211–10.136

0.700

P-wave duration ≥ 150 ms

15.000

5.593–40.227

< 0.001

9.503

2.479–36.432

0.001

  1. Data are presented as an odd ratio with 95% CI. A two-tailed p value < 0.05 was considered significant
  2. Time to treatment = time from first clinical diagnosis of AF to ablation procedure
  3. Abbreviations
  4. LVZ; low voltage zone; OR = odds ratio; CI = confidence interval; OSA = obstructive sleep apnea; BMI = body mass index; eGFR = estimated glomerular filtration rate; LAIVI = left atrial intracavitary volume index; AF = atrial fibrillation
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us